<DOC>
	<DOCNO>NCT01550965</DOCNO>
	<brief_summary>This study evaluate quality life ( QOL ) economic impact adalimumab treatment participant ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>A Study Evaluate Impact Adalimumab Quality Life , Health Care Utilization Costs Ulcerative Colitis Subjects Usual Clinical Practice Setting</brief_title>
	<detailed_description>This single arm , open-label , multicenter study . The primary objective study effect adalimumab QOL ( measure Short Inflammatory Bowel Disease Questionnaire ( SIBDQ ) ) , utilization health care resource , cost care subject UC treat adalimumab usual clinical practice set . The secondary objective assess effect adalimumab disease activity collect additional safety data subject UC .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Participants male female age 18 75 year old time Screening Visit . 2 . Participants diagnosis ulcerative colitis ( UC ) great 90 day prior baseline ( week 0 ) fail conventional treatment . 3 . Participants diagnosis active UC confirm colonoscopy biopsy flexible sigmoidoscopy biopsy . 4 . Participants active UC Physicians Global Assessment ( PGA ) score 2 3 Short Inflammatory Bowel Disease Questionnaire ( SIBDQ ) ≤ 45 baseline ( week 0 ) . 5 . Concurrent therapy require participant previously treat corticosteroid immunosuppressant ( azathioprine ( AZA ) 6mercaptopurine ( 6MP ) ) , judgment investigator , fail respond could tolerate treatment . Participants concurrent treatment least one follow ( oral corticosteroid immunosuppressant define ) : Stable oral corticosteroid dose ( prednisone ≥ 20 mg/day equivalent ) least 14 day prior baseline , Stable oral corticosteroid dose ( prednisone &lt; 20 mg/day ) least 21 day prior baseline , and/or At least consecutive 12 week ( 84 day ) course AZA 6MP prior baseline . 1 . Participants history subtotal colectomy ileorectostomy colectomy ileoanal pouch , Kock pouch , ileostomy UC plan bowel surgery . 2 . Participants receive previous treatment adalimumab previous participation adalimumab clinical study . 3 . Participants previously use infliximab anti tumor necrosis factor ( TNF ) agent within 56 day baseline ( week 0 ) . 4 . Participants previously use infliximab antiTNF agent clinically respond time ( `` primary nonresponder '' ) unless experience treatment limit reaction . 5 . Participants receive cyclosporine , tacrolimus , mycophenolate mofetil within 30 day baseline ( week 0 ) . 6 . Participants receive intravenous ( IV ) corticosteroid within 14 day Screening screening period . 7 . Participants current diagnosis fulminant colitis and/or toxic megacolon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Quality Life</keyword>
	<keyword>Costs Ulcerative Colitis</keyword>
	<keyword>Health Care Utilization</keyword>
</DOC>